hydrocodone bitartrate and acetaminophen — Competitive Intelligence Brief

hydrocodone bitartrate and acetaminophen (hydrocodone bitartrate and acetaminophen) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Neuroscience.

discontinued Neuroscience Small molecule

Target snapshot

hydrocodone bitartrate and acetaminophen (hydrocodone bitartrate and acetaminophen) — Rush University Medical Center. Mechanism of Action Hydrocodone is full opioid agonist with relative selectivity for the mu-opioid (μ) receptor, although it can interact with other opioid receptors at higher doses. The principal therapeutic action of hydrocodone is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia with hydrocodone. Clinically, dosage is titrated to provide adequate analgesia and may be limited by adverse reactions, including respiratory and CNS depression. The precise mechanism of the analgesic action is unknown. However, specific CNS opioid receptors for endogenous compounds with opioid-like activity have been identified throughout the brain and spinal cord and are thought to play a role in the analgesic effects of this drug. The precise mechanism of the analgesic properties of acetaminophen is not established but is thought to involve central actions.

Comparator set

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
hydrocodone bitartrate and acetaminophen TARGET	hydrocodone bitartrate and acetaminophen	Rush University Medical Center	discontinued

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.